Federation des caisses Desjardins du Quebec’s Heron Therapeutics HRTX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-915	Closed	-$14.8K	–	2543
2021 Q1	$14.8K	Hold	915	–	–	﹤0.01%	1892
2020 Q4	$19.4K	Hold	915	–	–	﹤0.01%	1748
2020 Q3	$13.6K	Buy	+915	New	+$14.3K	﹤0.01%	1603

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's HRTX Position: Q2 2021 in Review

Federation des caisses Desjardins du Quebec sold out of Heron Therapeutics (HRTX) in Q2 2021, closing a stake of 915 shares — an estimated $14.8K sold.

Federation des caisses Desjardins du Quebec first reported a position in HRTX in Q3 2020 and held it in 3 quarters. The position peaked at $19.4K in Q4 2020. 189 funds tracked by Wall St. Rank hold HRTX as of Q2 2021.

Federation des caisses Desjardins du Quebec reported no remaining Heron Therapeutics position as of Q2 2021 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 915 Heron Therapeutics shares in Q2 2021, an estimated $14.8K.
Federation des caisses Desjardins du Quebec first reported a position in Heron Therapeutics in Q3 2020 and held it in 3 quarters.
Federation des caisses Desjardins du Quebec's Heron Therapeutics position peaked at $19.4K in Q4 2020.
189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2021.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2021, filed 30 Aug 2024.